Skip to main content
Top
Published in: BMC Infectious Diseases 1/2014

Open Access 01-12-2014 | Research article

Oral antibiotic therapy for the treatment of infective endocarditis: a systematic review

Authors: Awad Al-Omari, D William Cameron, Craig Lee, Vicente F Corrales-Medina

Published in: BMC Infectious Diseases | Issue 1/2014

Login to get access

Abstract

Background

The role of oral antibiotic therapy in treating infective endocarditis (IE) is not well established.

Methods

We searched MEDLINE, EMBASE and Scopus for studies in which oral antibiotic therapy was used for the treatment of IE.

Results

Seven observational studies evaluating the use oral beta-lactams (five), oral ciprofloxacin in combination with rifampin (one), and linezolid (one) for the treatment of IE caused by susceptible bacteria reported cure rates between 77% and 100%. Two other observational studies using aureomycin or sulfonamide, however, had failure rates >75%. One clinical trial comparing oral amoxicillin versus intravenous ceftriaxone for streptococcal IE reported 100% cure in both arms but its reporting had serious methodological limitations. One small clinical trial (n = 85) comparing oral ciprofloxacin and rifampin versus conventional intravenous antibiotic therapy for uncomplicated right-sided S. aureus IE in intravenous drug users (IVDUs) reported cure rates of 89% and 90% in each arm, respectively (P =0.9); however, drug toxicities were more common in the latter group (62% versus 3%; P <0.01). Major limitations of this trial were lack of allocation concealment and blinding at the delivery of the study drug(s) and assessment of outcomes.

Conclusion

Reported cure rates for IE treated with oral antibiotic regimens vary widely. The use of oral ciprofloxacin in combination with rifampin for uncomplicated right-sided S. aureus IE in IVDUs is supported by one small clinical trial of relatively good quality and could be considered when conventional IV antibiotic therapy is not possible.
Appendix
Available only for authorised users
Literature
1.
go back to reference Mylonakis E, Calderwood SB: Infective endocarditis in adults. N Engl J Med. 2001, 345 (18): 1318-1330. 10.1056/NEJMra010082.CrossRefPubMed Mylonakis E, Calderwood SB: Infective endocarditis in adults. N Engl J Med. 2001, 345 (18): 1318-1330. 10.1056/NEJMra010082.CrossRefPubMed
2.
go back to reference Que YA, Moreillon P: Infective endocarditis. Nat Rev Cardiol. 2011, 8 (6): 322-336. 10.1038/nrcardio.2011.43.CrossRefPubMed Que YA, Moreillon P: Infective endocarditis. Nat Rev Cardiol. 2011, 8 (6): 322-336. 10.1038/nrcardio.2011.43.CrossRefPubMed
3.
go back to reference Wilson WR, Gilbert DN, Bisno AL, Freedman LR, Smith C, Drusano G, Kaye D: Evaluation of new anti-infective drugs for the treatment of infective endocarditis. Infectious Diseases Society of America and the Food and Drug Administration. Clin Infect Dis. 1992, 15 Suppl 1: S89-95.CrossRefPubMed Wilson WR, Gilbert DN, Bisno AL, Freedman LR, Smith C, Drusano G, Kaye D: Evaluation of new anti-infective drugs for the treatment of infective endocarditis. Infectious Diseases Society of America and the Food and Drug Administration. Clin Infect Dis. 1992, 15 Suppl 1: S89-95.CrossRefPubMed
4.
go back to reference Cunha BA: Oral antibiotic therapy of serious systemic infections. Med Clin North Am. 2006, 90 (6): 1197-1222. 10.1016/j.mcna.2006.07.009.CrossRefPubMed Cunha BA: Oral antibiotic therapy of serious systemic infections. Med Clin North Am. 2006, 90 (6): 1197-1222. 10.1016/j.mcna.2006.07.009.CrossRefPubMed
5.
go back to reference Baddour LM, Wilson WR, Bayer AS, Fowler VG, Bolger AF, Levison ME, Ferrieri P, Gerber MA, Tani LY, Gewitz MH, Tong DC, Steckelberg JM, Baltimore RS, Shulman ST, Burns JC, Falace DA, Newburger JW, Pallasch TJ, Takahashi M, Taubert KA, Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease: Infective endocarditis: diagnosis, antimicrobial therapy, and management of complications: a statement for healthcare professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association: endorsed by the Infectious Diseases Society of America. Circulation. 2005, 111 (23): e394-434. 10.1161/CIRCULATIONAHA.105.165564.CrossRefPubMed Baddour LM, Wilson WR, Bayer AS, Fowler VG, Bolger AF, Levison ME, Ferrieri P, Gerber MA, Tani LY, Gewitz MH, Tong DC, Steckelberg JM, Baltimore RS, Shulman ST, Burns JC, Falace DA, Newburger JW, Pallasch TJ, Takahashi M, Taubert KA, Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease: Infective endocarditis: diagnosis, antimicrobial therapy, and management of complications: a statement for healthcare professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association: endorsed by the Infectious Diseases Society of America. Circulation. 2005, 111 (23): e394-434. 10.1161/CIRCULATIONAHA.105.165564.CrossRefPubMed
6.
go back to reference Moher D, Liberati A, Tetzlaff J, Altman DG: Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009, 151 (4): 264-269. 10.7326/0003-4819-151-4-200908180-00135. W264CrossRefPubMed Moher D, Liberati A, Tetzlaff J, Altman DG: Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009, 151 (4): 264-269. 10.7326/0003-4819-151-4-200908180-00135. W264CrossRefPubMed
7.
go back to reference How to read clinical journals: III. To learn the clinical course and prognosis of disease. Can Med Assoc J. 1981, 124 (7): 869-872. How to read clinical journals: III. To learn the clinical course and prognosis of disease. Can Med Assoc J. 1981, 124 (7): 869-872.
8.
go back to reference Moher D, Schulz KF, Altman DG: The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials. Lancet. 2001, 357 (9263): 1191-1194. 10.1016/S0140-6736(00)04337-3.CrossRefPubMed Moher D, Schulz KF, Altman DG: The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials. Lancet. 2001, 357 (9263): 1191-1194. 10.1016/S0140-6736(00)04337-3.CrossRefPubMed
9.
go back to reference Colli A, Campodonico R, Gherli T: Early switch from vancomycin to oral linezolid for treatment of gram-positive heart valve endocarditis. Ann Thorac Surg. 2007, 84 (1): 87-91. 10.1016/j.athoracsur.2007.02.096.CrossRefPubMed Colli A, Campodonico R, Gherli T: Early switch from vancomycin to oral linezolid for treatment of gram-positive heart valve endocarditis. Ann Thorac Surg. 2007, 84 (1): 87-91. 10.1016/j.athoracsur.2007.02.096.CrossRefPubMed
10.
go back to reference Dworkin RJ, Lee BL, Sande MA, Chambers HF: Treatment of right-sided Staphylococcus aureus endocarditis in intravenous drug users with ciprofloxacin and rifampicin. Lancet. 1989, 2 (8671): 1071-1073.CrossRefPubMed Dworkin RJ, Lee BL, Sande MA, Chambers HF: Treatment of right-sided Staphylococcus aureus endocarditis in intravenous drug users with ciprofloxacin and rifampicin. Lancet. 1989, 2 (8671): 1071-1073.CrossRefPubMed
11.
go back to reference Chetty S, Mitha AS: High-dose oral amoxycillin in the treatment of infective endocarditis. S Afr Med J. 1988, 73 (12): 709-710.PubMed Chetty S, Mitha AS: High-dose oral amoxycillin in the treatment of infective endocarditis. S Afr Med J. 1988, 73 (12): 709-710.PubMed
12.
go back to reference Pinchas A, Lessing J, Siegman-Igra Y, Liron M: Oral treatment of bacterial endocarditis. Isr J Med Sci. 1983, 19 (7): 646-648.PubMed Pinchas A, Lessing J, Siegman-Igra Y, Liron M: Oral treatment of bacterial endocarditis. Isr J Med Sci. 1983, 19 (7): 646-648.PubMed
13.
14.
go back to reference Gray IR, Tai AR, Wallace JG, Calder JH: Oral treatment of bacterial endocarditis with penicillins. Lancet. 1964, 2 (7351): 110-114.CrossRefPubMed Gray IR, Tai AR, Wallace JG, Calder JH: Oral treatment of bacterial endocarditis with penicillins. Lancet. 1964, 2 (7351): 110-114.CrossRefPubMed
15.
go back to reference Campeau L, Lefebvre M: Oral treatment of malignant streptococcal endocarditis by potassium phenethicillin: 10 cases. Union Med Can. 1963, 92: 873-880.PubMed Campeau L, Lefebvre M: Oral treatment of malignant streptococcal endocarditis by potassium phenethicillin: 10 cases. Union Med Can. 1963, 92: 873-880.PubMed
16.
go back to reference Friedberg CK: Treatment of subacute bacterial endocarditis with aureomycin. J Am Med Assoc. 1952, 148 (2): 98-103.CrossRefPubMed Friedberg CK: Treatment of subacute bacterial endocarditis with aureomycin. J Am Med Assoc. 1952, 148 (2): 98-103.CrossRefPubMed
17.
go back to reference Schein J, Baehr G: Sulfonamide therapy of subacute bacterial endocarditis. Am J Med. 1948, 4 (1): 66-72. 10.1016/0002-9343(48)90373-8.CrossRefPubMed Schein J, Baehr G: Sulfonamide therapy of subacute bacterial endocarditis. Am J Med. 1948, 4 (1): 66-72. 10.1016/0002-9343(48)90373-8.CrossRefPubMed
18.
go back to reference Heldman AW, Hartert TV, Ray SC, Daoud EG, Kowalski TE, Pompili VJ, Sisson SD, Tidmore WC, Vom Eigen KA, Goodman SN, Lietman PS, Petty BG, Flexner C: Oral antibiotic treatment of right-sided staphylococcal endocarditis in injection drug users: prospective randomized comparison with parenteral therapy. Am J Med. 1996, 101 (1): 68-76. 10.1016/S0002-9343(96)00070-8.CrossRefPubMed Heldman AW, Hartert TV, Ray SC, Daoud EG, Kowalski TE, Pompili VJ, Sisson SD, Tidmore WC, Vom Eigen KA, Goodman SN, Lietman PS, Petty BG, Flexner C: Oral antibiotic treatment of right-sided staphylococcal endocarditis in injection drug users: prospective randomized comparison with parenteral therapy. Am J Med. 1996, 101 (1): 68-76. 10.1016/S0002-9343(96)00070-8.CrossRefPubMed
19.
go back to reference Stamboulian D, Bonvehi P, Arevalo C, Bologna R, Cassetti I, Scilingo V, Efron E: Antibiotic management of outpatients with endocarditis due to penicillin-susceptible streptococci. Rev Infect Dis. 1991, 13 (Suppl 2): S160-163.CrossRefPubMed Stamboulian D, Bonvehi P, Arevalo C, Bologna R, Cassetti I, Scilingo V, Efron E: Antibiotic management of outpatients with endocarditis due to penicillin-susceptible streptococci. Rev Infect Dis. 1991, 13 (Suppl 2): S160-163.CrossRefPubMed
20.
go back to reference Lafforgue G, Arellano C, Vachoux C, Woodley J, Philibert C, Dupouy V, Bousquet-Melou A, Gandia P, Houin G: Oral absorption of ampicillin: role of paracellular route vs. PepT1 transporter. Fundam Clin Pharmacol. 2008, 22 (2): 189-201. 10.1111/j.1472-8206.2008.00572.x.CrossRefPubMed Lafforgue G, Arellano C, Vachoux C, Woodley J, Philibert C, Dupouy V, Bousquet-Melou A, Gandia P, Houin G: Oral absorption of ampicillin: role of paracellular route vs. PepT1 transporter. Fundam Clin Pharmacol. 2008, 22 (2): 189-201. 10.1111/j.1472-8206.2008.00572.x.CrossRefPubMed
21.
go back to reference Gordon C, Regamey C, Kirby WM: Comparative clinical pharmacology of amoxicillin and ampicillin administered orally. Antimicrob Agents Chemother. 1972, 1 (6): 504-507. 10.1128/AAC.1.6.504.CrossRefPubMedPubMedCentral Gordon C, Regamey C, Kirby WM: Comparative clinical pharmacology of amoxicillin and ampicillin administered orally. Antimicrob Agents Chemother. 1972, 1 (6): 504-507. 10.1128/AAC.1.6.504.CrossRefPubMedPubMedCentral
22.
23.
go back to reference Gray IR: The choice of antibiotic for treating infective endocarditis. Q J Med. 1975, 44 (175): 449-458.PubMed Gray IR: The choice of antibiotic for treating infective endocarditis. Q J Med. 1975, 44 (175): 449-458.PubMed
24.
go back to reference Moreno RA, Boldrina L, Guermani A, Mazucheli J, Sverdloff C, Borges NC: Comparative bioavailability study of two phenoxymethylpenicillin potassium tablet formulations in healthy volunteers. Int J Clin Pharmacol Ther. 2007, 45 (12): 669-676. 10.5414/CPP45669.CrossRefPubMed Moreno RA, Boldrina L, Guermani A, Mazucheli J, Sverdloff C, Borges NC: Comparative bioavailability study of two phenoxymethylpenicillin potassium tablet formulations in healthy volunteers. Int J Clin Pharmacol Ther. 2007, 45 (12): 669-676. 10.5414/CPP45669.CrossRefPubMed
25.
go back to reference Watanakunakorn C: The use of beta-lactam antibiotics in the treatment of septicaemia and endocarditis. Scand J Infect Dis Suppl. 1984, 42: 110-116.PubMed Watanakunakorn C: The use of beta-lactam antibiotics in the treatment of septicaemia and endocarditis. Scand J Infect Dis Suppl. 1984, 42: 110-116.PubMed
26.
go back to reference Sabath LD: Phenoxymethylpenicillin (penicillin V) and phenethicillin. Med Clin North Am. 1970, 54 (5): 1101-1111.PubMed Sabath LD: Phenoxymethylpenicillin (penicillin V) and phenethicillin. Med Clin North Am. 1970, 54 (5): 1101-1111.PubMed
27.
go back to reference Bolon MK: The newer fluoroquinolones. Infect Dis Clin North Am. 2009, 23 (4): 1027-1051. 10.1016/j.idc.2009.06.003. xCrossRefPubMed Bolon MK: The newer fluoroquinolones. Infect Dis Clin North Am. 2009, 23 (4): 1027-1051. 10.1016/j.idc.2009.06.003. xCrossRefPubMed
28.
go back to reference Kaatz GW, Barriere SL, Schaberg DR, Fekety R: The emergence of resistance to ciprofloxacin during treatment of experimental Staphylococcus aureus endocarditis. J Antimicrob Chemother. 1987, 20 (5): 753-758. 10.1093/jac/20.5.753.CrossRefPubMed Kaatz GW, Barriere SL, Schaberg DR, Fekety R: The emergence of resistance to ciprofloxacin during treatment of experimental Staphylococcus aureus endocarditis. J Antimicrob Chemother. 1987, 20 (5): 753-758. 10.1093/jac/20.5.753.CrossRefPubMed
29.
go back to reference Zak O, Scheld WM, Sande MA: Rifampin in experimental endocarditis due to Staphylococcus aureus in rabbits. Rev Infect Dis. 1983, 5 (Suppl 3): S481-490.CrossRefPubMed Zak O, Scheld WM, Sande MA: Rifampin in experimental endocarditis due to Staphylococcus aureus in rabbits. Rev Infect Dis. 1983, 5 (Suppl 3): S481-490.CrossRefPubMed
30.
go back to reference Hackbarth CJ, Chambers HF, Sande MA: Serum bactericidal activity of rifampin in combination with other antimicrobial agents against Staphylococcus aureus. Antimicrob Agents Chemother. 1986, 29 (4): 611-613. 10.1128/AAC.29.4.611.CrossRefPubMedPubMedCentral Hackbarth CJ, Chambers HF, Sande MA: Serum bactericidal activity of rifampin in combination with other antimicrobial agents against Staphylococcus aureus. Antimicrob Agents Chemother. 1986, 29 (4): 611-613. 10.1128/AAC.29.4.611.CrossRefPubMedPubMedCentral
31.
go back to reference Kaatz GW, Seo SM, Barriere SL, Albrecht LM, Rybak MJ: Ciprofloxacin and rifampin, alone and in combination, for therapy of experimental Staphylococcus aureus endocarditis. Antimicrob Agents Chemother. 1989, 33 (8): 1184-1187. 10.1128/AAC.33.8.1184.CrossRefPubMedPubMedCentral Kaatz GW, Seo SM, Barriere SL, Albrecht LM, Rybak MJ: Ciprofloxacin and rifampin, alone and in combination, for therapy of experimental Staphylococcus aureus endocarditis. Antimicrob Agents Chemother. 1989, 33 (8): 1184-1187. 10.1128/AAC.33.8.1184.CrossRefPubMedPubMedCentral
32.
go back to reference Tebas P, Martinez Ruiz R, Roman F, Mendaza P, Rodriguez Diaz JC, Daza R, de Letona JM: Early resistance to rifampin and ciprofloxacin in the treatment of right-sided Staphylococcus aureus endocarditis. J Infect Dis. 1991, 163 (1): 204-205.CrossRefPubMed Tebas P, Martinez Ruiz R, Roman F, Mendaza P, Rodriguez Diaz JC, Daza R, de Letona JM: Early resistance to rifampin and ciprofloxacin in the treatment of right-sided Staphylococcus aureus endocarditis. J Infect Dis. 1991, 163 (1): 204-205.CrossRefPubMed
33.
go back to reference Dajcs JJ, Thibodeaux BA, Marquart ME, Girgis DO, Traidej M, O'Callaghan RJ: Effectiveness of ciprofloxacin, levofloxacin, or moxifloxacin for treatment of experimental Staphylococcus aureus keratitis. Antimicrob Agents Chemother. 2004, 48 (6): 1948-1952. 10.1128/AAC.48.6.1948-1952.2004.CrossRefPubMedPubMedCentral Dajcs JJ, Thibodeaux BA, Marquart ME, Girgis DO, Traidej M, O'Callaghan RJ: Effectiveness of ciprofloxacin, levofloxacin, or moxifloxacin for treatment of experimental Staphylococcus aureus keratitis. Antimicrob Agents Chemother. 2004, 48 (6): 1948-1952. 10.1128/AAC.48.6.1948-1952.2004.CrossRefPubMedPubMedCentral
34.
go back to reference Lister PD: Pharmacodynamics of moxifloxacin and levofloxacin against Staphylococcus aureus and Staphylococcus epidermidis in an in vitro pharmacodynamic model. Clin Infect Dis. 2001, 32 (Suppl 1): S33-38.CrossRefPubMed Lister PD: Pharmacodynamics of moxifloxacin and levofloxacin against Staphylococcus aureus and Staphylococcus epidermidis in an in vitro pharmacodynamic model. Clin Infect Dis. 2001, 32 (Suppl 1): S33-38.CrossRefPubMed
35.
go back to reference Entenza JM, Vouillamoz J, Glauser MP, Moreillon P: Levofloxacin versus ciprofloxacin, flucloxacillin, or vancomycin for treatment of experimental endocarditis due to methicillin-susceptible or -resistant Staphylococcus aureus. Antimicrob Agents Chemother. 1997, 41 (8): 1662-1667.PubMedPubMedCentral Entenza JM, Vouillamoz J, Glauser MP, Moreillon P: Levofloxacin versus ciprofloxacin, flucloxacillin, or vancomycin for treatment of experimental endocarditis due to methicillin-susceptible or -resistant Staphylococcus aureus. Antimicrob Agents Chemother. 1997, 41 (8): 1662-1667.PubMedPubMedCentral
36.
go back to reference Galani L, Pefanis A, Sakka V, Iliopoulos D, Donta I, Triantafyllidi H, Skiadas I, Karayiannakos P, Giamarellou H: Successful treatment with moxifloxacin of experimental aortic valve endocarditis due to methicillin-resistant Staphylococcus aureus (MRSA). Int J Antimicrob Agents. 2009, 33 (1): 65-69. 10.1016/j.ijantimicag.2008.07.021.CrossRefPubMed Galani L, Pefanis A, Sakka V, Iliopoulos D, Donta I, Triantafyllidi H, Skiadas I, Karayiannakos P, Giamarellou H: Successful treatment with moxifloxacin of experimental aortic valve endocarditis due to methicillin-resistant Staphylococcus aureus (MRSA). Int J Antimicrob Agents. 2009, 33 (1): 65-69. 10.1016/j.ijantimicag.2008.07.021.CrossRefPubMed
37.
go back to reference Berrington AW, Koerner RJ, Perry JD, Bain HH, Gould FK: Treatment of Staphylococcus aureus endocarditis using moxifloxacin. Int J Med Microbiol. 2001, 291 (3): 237-239. 10.1078/1438-4221-00126.CrossRefPubMed Berrington AW, Koerner RJ, Perry JD, Bain HH, Gould FK: Treatment of Staphylococcus aureus endocarditis using moxifloxacin. Int J Med Microbiol. 2001, 291 (3): 237-239. 10.1078/1438-4221-00126.CrossRefPubMed
38.
go back to reference Foo SS, Lye DC: Methicillin-sensitive Staphylococcus aureus tricuspid valve endocarditis with annular abscess cured with oral levofloxacin and rifampicin. Int J Antimicrob Agents. 2007, 30 (3): 275-277. 10.1016/j.ijantimicag.2007.04.008.CrossRefPubMed Foo SS, Lye DC: Methicillin-sensitive Staphylococcus aureus tricuspid valve endocarditis with annular abscess cured with oral levofloxacin and rifampicin. Int J Antimicrob Agents. 2007, 30 (3): 275-277. 10.1016/j.ijantimicag.2007.04.008.CrossRefPubMed
39.
go back to reference Dryden MS: Linezolid pharmacokinetics and pharmacodynamics in clinical treatment. J Antimicrob Chemother. 66 Suppl 4: iv7-iv15. Dryden MS: Linezolid pharmacokinetics and pharmacodynamics in clinical treatment. J Antimicrob Chemother. 66 Suppl 4: iv7-iv15.
40.
go back to reference Hall B: The absorption and distribution of aureomycin in man; a review of the literature and study of the concentration of aureomycin in the serum, urine and cerebrospinal fluid after oral administration. Ann Intern Med. 1954, 40 (4): 743-754.CrossRefPubMed Hall B: The absorption and distribution of aureomycin in man; a review of the literature and study of the concentration of aureomycin in the serum, urine and cerebrospinal fluid after oral administration. Ann Intern Med. 1954, 40 (4): 743-754.CrossRefPubMed
41.
go back to reference Rolain JM, Boulos A, Mallet MN, Raoult D: Correlation between ratio of serum doxycycline concentration to MIC and rapid decline of antibody levels during treatment of Q fever endocarditis. Antimicrob Agents Chemother. 2005, 49 (7): 2673-2676. 10.1128/AAC.49.7.2673-2676.2005.CrossRefPubMedPubMedCentral Rolain JM, Boulos A, Mallet MN, Raoult D: Correlation between ratio of serum doxycycline concentration to MIC and rapid decline of antibody levels during treatment of Q fever endocarditis. Antimicrob Agents Chemother. 2005, 49 (7): 2673-2676. 10.1128/AAC.49.7.2673-2676.2005.CrossRefPubMedPubMedCentral
42.
go back to reference Rolain JM, Mallet MN, Raoult D: Correlation between serum doxycycline concentrations and serologic evolution in patients with Coxiella burnetii endocarditis. J Infect Dis. 2003, 188 (9): 1322-1325. 10.1086/379082.CrossRefPubMed Rolain JM, Mallet MN, Raoult D: Correlation between serum doxycycline concentrations and serologic evolution in patients with Coxiella burnetii endocarditis. J Infect Dis. 2003, 188 (9): 1322-1325. 10.1086/379082.CrossRefPubMed
43.
go back to reference Cunha BA: Minocycline versus doxycycline for meticillin-resistant Staphylococcus aureus (MRSA): in vitro susceptibility versus in vivo effectiveness. Int J Antimicrob Agents. 2010, 35 (5): 517-518. 10.1016/j.ijantimicag.2010.01.017.CrossRefPubMed Cunha BA: Minocycline versus doxycycline for meticillin-resistant Staphylococcus aureus (MRSA): in vitro susceptibility versus in vivo effectiveness. Int J Antimicrob Agents. 2010, 35 (5): 517-518. 10.1016/j.ijantimicag.2010.01.017.CrossRefPubMed
44.
go back to reference Nicolau DP, Freeman CD, Nightingale CH, Coe CJ, Quintiliani R: Minocycline versus vancomycin for treatment of experimental endocarditis caused by oxacillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother. 1994, 38 (7): 1515-1518. 10.1128/AAC.38.7.1515.CrossRefPubMedPubMedCentral Nicolau DP, Freeman CD, Nightingale CH, Coe CJ, Quintiliani R: Minocycline versus vancomycin for treatment of experimental endocarditis caused by oxacillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother. 1994, 38 (7): 1515-1518. 10.1128/AAC.38.7.1515.CrossRefPubMedPubMedCentral
45.
go back to reference Clumeck N, Marcelis L, Amiri-Lamraski MH, Gordts B: Treatment of severe staphylococcal infections with a rifampicin-minocycline association. J Antimicrob Chemother. 1984, 13 Suppl C: 17-22.CrossRefPubMed Clumeck N, Marcelis L, Amiri-Lamraski MH, Gordts B: Treatment of severe staphylococcal infections with a rifampicin-minocycline association. J Antimicrob Chemother. 1984, 13 Suppl C: 17-22.CrossRefPubMed
46.
go back to reference Lawlor MT, Sullivan MC, Levitz RE, Quintiliani R, Nightingale C: Treatment of prosthetic valve endocarditis due to methicillin-resistant Staphylococcus aureus with minocycline. J Infect Dis. 1990, 161 (4): 812-814. 10.1093/infdis/161.4.812.CrossRefPubMed Lawlor MT, Sullivan MC, Levitz RE, Quintiliani R, Nightingale C: Treatment of prosthetic valve endocarditis due to methicillin-resistant Staphylococcus aureus with minocycline. J Infect Dis. 1990, 161 (4): 812-814. 10.1093/infdis/161.4.812.CrossRefPubMed
47.
go back to reference Markowitz N, Quinn EL, Saravolatz LD: Trimethoprim-sulfamethoxazole compared with vancomycin for the treatment of Staphylococcus aureus infection. Ann Intern Med. 1992, 117 (5): 390-398. 10.7326/0003-4819-117-5-390.CrossRefPubMed Markowitz N, Quinn EL, Saravolatz LD: Trimethoprim-sulfamethoxazole compared with vancomycin for the treatment of Staphylococcus aureus infection. Ann Intern Med. 1992, 117 (5): 390-398. 10.7326/0003-4819-117-5-390.CrossRefPubMed
48.
go back to reference Ono T, Shiota S, Hirota K, Nemoto K, Tsuchiya T, Miyake Y: Susceptibilities of oral and nasal isolates of Streptococcus mitis and Streptococcus oralis to macrolides and PCR detection of resistance genes. Antimicrob Agents Chemother. 2000, 44 (4): 1078-1080. 10.1128/AAC.44.4.1078-1080.2000.CrossRefPubMedPubMedCentral Ono T, Shiota S, Hirota K, Nemoto K, Tsuchiya T, Miyake Y: Susceptibilities of oral and nasal isolates of Streptococcus mitis and Streptococcus oralis to macrolides and PCR detection of resistance genes. Antimicrob Agents Chemother. 2000, 44 (4): 1078-1080. 10.1128/AAC.44.4.1078-1080.2000.CrossRefPubMedPubMedCentral
50.
go back to reference Prunier AL, Malbruny B, Tande D, Picard B, Leclercq R: Clinical isolates of Staphylococcus aureus with ribosomal mutations conferring resistance to macrolides. Antimicrob Agents Chemother. 2002, 46 (9): 3054-3056. 10.1128/AAC.46.9.3054-3056.2002.CrossRefPubMedPubMedCentral Prunier AL, Malbruny B, Tande D, Picard B, Leclercq R: Clinical isolates of Staphylococcus aureus with ribosomal mutations conferring resistance to macrolides. Antimicrob Agents Chemother. 2002, 46 (9): 3054-3056. 10.1128/AAC.46.9.3054-3056.2002.CrossRefPubMedPubMedCentral
51.
go back to reference Iversen K, Host N, Bruun NE, Elming H, Pump B, Christensen JJ, Gill S, Rosenvinge F, Wiggers H, Fuursted K, Holst-Hansen C, Korup E, Schønheyder HC, Hassager C, Høfsten D, Larsen JH, Moser C, Ihlemann N, Bundgaard H: Partial oral treatment of endocarditis. Am Heart J. 2013, 165 (2): 116-122. 10.1016/j.ahj.2012.11.006.CrossRefPubMed Iversen K, Host N, Bruun NE, Elming H, Pump B, Christensen JJ, Gill S, Rosenvinge F, Wiggers H, Fuursted K, Holst-Hansen C, Korup E, Schønheyder HC, Hassager C, Høfsten D, Larsen JH, Moser C, Ihlemann N, Bundgaard H: Partial oral treatment of endocarditis. Am Heart J. 2013, 165 (2): 116-122. 10.1016/j.ahj.2012.11.006.CrossRefPubMed
Metadata
Title
Oral antibiotic therapy for the treatment of infective endocarditis: a systematic review
Authors
Awad Al-Omari
D William Cameron
Craig Lee
Vicente F Corrales-Medina
Publication date
01-12-2014
Publisher
BioMed Central
Published in
BMC Infectious Diseases / Issue 1/2014
Electronic ISSN: 1471-2334
DOI
https://doi.org/10.1186/1471-2334-14-140

Other articles of this Issue 1/2014

BMC Infectious Diseases 1/2014 Go to the issue